Clinical Trial Update: DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations [Phase 2, Phase 3]

View source ↗

Summary

An ongoing DETERMINE trial (arm 06) investigates capmatinib for MET-dysregulated cancers, with Phase 2/3 testing and current recruitment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Glioma
• Hematological Malignancy
• Neuroblastoma
• Soft Tissue Sarcoma

Drugs mentioned

• Capmatinib (capmatinib)

Snippet

Sponsor: Cancer Research UK | Conditions: Solid Tumour, Haematological Malignancy | Phase 2, Phase 3 | Status: RECRUITING